When might retatrutide receive regulatory approval?

Eli Lilly has not announced a specific timeline but plans to submit regulatory applications soon.

How does retatrutide compare to other obesity drugs?

Retatrutide is a triple receptor agonist, while Mounjaro (tirzepatide) is a dual agonist and Wegovy (semaglutide) is a single agonist. The triple mechanism may offer greater weight loss efficacy.

Eli Lilly Reports Positive Phase 3 Results for Obesity Drug Retatrutide

Q: How many participants were in the TRIUMPH-1 trial?

The trial enrolled 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes.

Eli Lilly announced positive Phase 3 results from the TRIUMPH-1 trial of retatrutide, an investigational once-weekly triple hormone receptor agonist for obesity in adults without diabetes, with all doses meeting primary endpoints.

By: Wrqti Editorial

May 23, 2026

2 min read

Source: Insider Monkey

Key Numbers

study duration weeks

participants

2339

Eli Lilly and Company (NYSE:LLY) announced positive Phase 3 results from the TRIUMPH-1 trial of retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon) for obesity. The 80-week study enrolled 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes.

Study Details

All doses of retatrutide met the primary endpoint of significant weight reduction compared to placebo. The company did not disclose exact weight loss percentages but confirmed statistical and clinical significance.

Mechanism of Action

Retatrutide targets three hormone receptors: GIP, GLP-1, and glucagon, enhancing satiety and energy expenditure. This triple mechanism may offer advantages over dual agonists like tirzepatide (Mounjaro).

Competitive Landscape

Retatrutide competes with existing obesity drugs such as Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly). If approved, it could reshape the obesity treatment market, projected to reach $100 billion by 2030.

Potential Impact on Eli Lilly

Retatrutide could strengthen Eli Lilly's position in the growing obesity market and significantly boost revenue. The company plans to submit regulatory applications soon.

Frequently Asked Questions

Retatrutide is an investigational once-weekly obesity treatment that targets three hormone receptors (GIP, GLP-1, and glucagon).

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.